Crinetics Pharmaceuticals Inc.

This study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects,…

This Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…

This study tested a new drug called atumelnant in 21 healthy adults from Japanese and Caucasian backgrounds. The goal was to see how the drug moves through the body and if it is safe. Participants took the drug or a placebo by mouth once daily. This early-stage study does not aim…